Log In
Print
BCIQ
Print
Print this Print this
 

Dalvance, Xydalba, dalbavancin (RQ-00000002)

Also known as: formerly Exulett, Zeven

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionSecond-generation glycopeptide antibiotic
Molecular Target D-alanyl-D-alanine
Mechanism of ActionCell wall synthesis inhibitor
Therapeutic ModalityPeptide

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$903.0M

$690.0M

$213.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today